TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer

Carcinogenesis

Volumn 34, Issue 11, 2013, Pages 2525-2530

  Schabath, Matthew B ^a   Giuliano, Anna R ^a   Thompson, Zachary J ^a   Amankwah, Ernest K ^a   Gray, Jhanelle E ^a   Fenstermacher, David A ^a   Jonathan, Kristen A ^a   Beg, Amer A ^a   Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 13; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALLELE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HUMAN; IFNAR1 GENE; IL10RB GENE; INFLAMMATION; INTRON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PPARD GENE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TGFBR1 GENE; TGFBR2 GENE; TNFRSF10B GENE;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84887001533     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt244     Document Type: Article

References (44)

1. McErlean,A.et al. (2011) Epidemiology of lung cancer. Semin. Roentgenol., 46, 173-177.
2. Mirsadraee,S.et al. (2012) The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J. Radiol., 4, 128-134.
3. Dranoff,G. (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer, 4, 11-22.
4. Wolf,S.F.et al. (2000) Cytokines and cancer immunotherapy. Immunol. Invest., 29, 143-146.
5. Smyth,M.J.et al. (2004) Cytokines in cancer immunity and immunotherapy. Immunol. Rev., 202, 275-293.
6. Guan,X.et al. (2011) TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer, 11, 447.
7. Wu,X.et al. (2011) Genome-wide association study of survival in nonsmall cell lung cancer patients receiving platinum-based chemotherapy. J. Natl Cancer Inst., 103, 817-825.
8. Hildebrandt,M.A.et al. (2010) Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One, 5, e12402.
9. Reyes-Gibby,C.C.et al. (2009) Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol. Biomarkers Prev., 18, 2636-2642.
10. Wang,Y.C.et al. (2012) Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One, 7, e39525.
11. Niu,X.et al. (2012) A study of ethnic differences in TGFβ1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer. J. Thorac. Oncol., 7, 1668-1675.
12. Efron,B.et al. (1993) An Introduction to the Bootstrap. Chapman & Hall, New York, NY.
13. Benjamini,Y.et al. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B. Stat. Methodol., 57, 289-300.
14. Sheridan,J.P.et al. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818-821.
15. LeBlanc,H.N.et al. (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ., 10, 66-75.
16. Ashkenazi,A.et al. (1998) Death receptors: signaling and modulation. Science, 281, 1305-1308.
17. Lee,S.et al. (2011) Cytokines in cancer immunotherapy. Cancers, 3, 3856-3893.
18. Han,J.Y.et al. (2003) Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med. Oncol., 20, 355-362.
19. Leithner,K.et al. (2009) Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer, 65, 98-104.
20. Wistuba,I.I.et al. (1999) Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res., 59, 1973-1979.
21. Lee,S.H.et al. (1999) Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res., 59, 5683-5686.
22. Bidwell,J.et al. (1999) Cytokine gene polymorphism in human disease: on-line databases. Genes Immun., 1, 3-19.
23. Laurincov,B. (2000) Interleukin-1 family: from genes to human disease. Acta Univ. Palacki. Olomuc. Fac. Med., 143, 19-29.
24. Xu,Z.et al. (2009) SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res., 37, W600-W605.
25. Guo,L.et al. (2010) Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur. J. Cancer, 46, 1692-1702.
26. Okamoto,K.et al. (2012) miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver. EMBO J., 31, 1752-1763.
27. Hebsgaard,S.M.et al. (1996) Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res., 24, 3439-3452.
28. Tabaska,J.E.et al. (1999) Detection of polyadenylation signals in human DNA sequences. Gene, 231, 77-86.
29. Griffiths-Jones,S.et al. (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res., 36, D154-D158.
30. Lee,P.H.et al. (2008) F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res., 36, D820-D824.
31. Kent,W.J.et al. (2002) The human genome browser at UCSC. Genome Res., 12, 996-1006.
32. Lee,E.B.et al. (2010) Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer. Ann. Surg. Oncol., 17, 2608-2618.
33. Chen,B.et al. (2009) TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur. J. Cancer, 45, 2598-2605.
34. Körner,C.et al. (2012) TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer, 12, 85.
35. Mittal,R.D.et al. (2011) Association of death receptor 4, Caspase 3 and 5 gene polymorphism with increased risk to bladder cancer in North Indians. Eur. J. Surg. Oncol., 37, 727-733.
36. Dick,M.G.et al. (2012) Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers. Int. J. Cancer, 130, 1314-1318.
37. Hunter,T.B.et al. (2011) Paclitaxel and TRAIL synergize to kill paclitaxelresistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res., 31, 3193-3204.
38. Lu,P.H.et al. (2011) Paclitaxel induces apoptosis through activation of nuclear protein kinase C-δ and subsequent activation of Golgi associated Cdk1 in human hormone refractory prostate cancer. J. Urol., 186, 2434-2441.
39. Nagane,M.et al. (2001) The potential of TRAIL for cancer chemotherapy. Apoptosis, 6, 191-197.
40. Nagane,M.et al. (2010) Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro. Oncol., 12, 687-700.
41. Gibson,S.B.et al. (2000) Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol. Cell. Biol., 20, 205-212.
42. Liu,X.et al. (2007) The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res., 67, 4981-4988.
43. Su,L.et al. (2011) Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur. J. Cancer, 47, 2471-2478.
44. Gorlov,I.P.et al. (2011) Evolutionary evidence of the effect of rare variants on disease etiology. Clin. Genet., 79, 199-206.